Skip Navigation


NDT Advance Access originally published online on July 19, 2005
Nephrology Dialysis Transplantation 2005 20(10):2186-2193; doi:10.1093/ndt/gfh966
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/10/2186    most recent
gfh966v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (45)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moe, S. M.
Right arrow Articles by Sprague, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moe, S. M.
Right arrow Articles by Sprague, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Original Article

Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl

Sharon M. Moe1, John Cunningham2, Jürgen Bommer3, Stephen Adler4, Steven J. Rosansky5, Pablo Urena-Torres6, Moetaz B. Albizem7, Matthew D. Guo7, Valter J. Zani7, William G. Goodman8 and Stuart M. Sprague9

1 Indiana University School of Medicine and Roudebush VAMC, Indianapolis, IN, USA, 2 The Middlesex Hospital, London, UK, 3 Klinikum der Universität Heidelberg, Heidelberg, Germany, 4 Westchester Medical Center, NY Med College, Valhalla, NY, USA, 5 WJB Dorn Veterans Hospital, Columbia, SC, USA, 6 Clinique de l'Orangerie, Aubervillers, France, 7 Amgen Inc, Thousand Oaks, CA, USA, 8 UCLA School of Medicine, Los Angeles, CA, USA and 9 Evanston Northwestern Healthcare and Northwestern University Feinberg School of Medicine, Evanston, IL, USA

Correspondence and offprint requests to: Sharon M. Moe, Indiana University Department of Medicine, 1001 West 10th Street, OPW 526, Indianapolis, IN 46202, USA. Email: smoe{at}iupui.edu

Background. Patients with secondary hyperparathyroidism often require therapy that provides long-term control of parathyroid hormone concentrations without increasing calcium and phosphorus concentrations. Cinacalcet modulates the calcium-sensing receptor on the parathyroid gland to reduce secretion of parathyroid hormone and lower serum calcium, phosphorus and calcium–phosphorus product in haemodialysis patients.

Methods. Dialysis patients with secondary hyperparathyroidism [parathyroid hormone (PTH) level ≥300 pg/ml] who were enrolled in one of four phase 2 placebo-controlled studies were eligible to enrol in an open-label extension study in which all patients received cinacalcet. For this extension study, cinacalcet was initiated at 30 mg in all patients and the dose was escalated to a maximum of 180 mg once daily if PTH concentrations were >250 pg/ml. Use of concomitant vitamin D sterols and phosphate binders was not restricted.

Results. The analysis of all patients (n = 59) completing 100 weeks of cinacalcet treatment showed long-term control of PTH and calcium–phosphorus product. Approximately 55% achieved a PTH concentration ≤300 pg/ml at the week-100 study visit, and ~60% had at least a 30% reduction in PTH from baseline. Serum calcium, phosphorus and the calcium–phosphorus product did not increase during the study. Concomitant vitamin D sterol and phosphate binder therapy remained stable. Cinacalcet was safe and generally well tolerated at doses up to 180 mg/day.

Conclusions. In this long-term study, cinacalcet effectively sustained reductions in PTH for up to 3 years without increasing concentrations of serum calcium, phosphorus or calcium–phosphorus product.

Keywords: calcium-sensing receptor; chronic kidney disease; end-stage renal disease; haemodialysis; parathyroid hormone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
K. Yokoyama
Cinacalcet Hydrochloride in Chronic Kidney Disease-Mineral Bone Disorder
Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1405 - 1408.
[Full Text] [PDF]

Home page
 CJASNHome page
S. M. Sprague, P. Evenepoel, M. P. Curzi, M. T. Gonzalez, F. E. Husserl, N. Kopyt, L. R. Sterling, C. Mix, and G. Wong
Simultaneous Control of PTH and CaxP Is Sustained over Three Years of Treatment with Cinacalcet HCl
Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1465 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
A Connor
Novel therapeutic agents and strategies for the management of chronic kidney disease mineral and bone disorder
Postgrad. Med. J., May 1, 2009; 85(1003): 274 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
M. Nechama, I. Z. Ben-Dov, J. Silver, and T. Naveh-Many
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD
Am J Physiol Renal Physiol, April 1, 2009; 296(4): F795 - F800.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Meola, I. Petrucci, and G. Barsotti
Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
Nephrol. Dial. Transplant., March 1, 2009; 24(3): 982 - 989.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
W. L. St. Peter, Q. Li, J. Liu, M. Persky, K. Nieman, C. Arko, and G. A. Block
Cinacalcet Use Patterns and Effect on Laboratory Values and Other Medications in a Large Dialysis Organization, 2004 through 2006
Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 354 - 360.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
T. B. Drueke and E. Ritz
Treatment of Secondary Hyperparathyroidism in CKD Patients with Cinacalcet and/or Vitamin D Derivatives
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 234 - 241.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
P. D. Miller
The Role of Bone Biopsy in Patients with Chronic Renal Failure
Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S140 - S150.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
J. J. Diez, J. L. Miguel, R. Codoceo, P. Iglesias, M. A. Bajo, C. Sanchez, G. del Peso, F. Gil, J. Martinez-Ara, P. G. Gancedo, et al.
Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1387 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Battistella, B. Hamandi, C. Pui, D. Oreopoulos, R. Richardson, and S. V. Jassal
Clinical remission as measured by a decrease in intact parathyroid hormone levels after administration of cinacalcet in patients with severe hyperparathyroidism
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 773 - 774.
[Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
S. Tomasello
Secondary Hyperparathyroidism and Chronic Kidney Disease
Diabetes Spectr, January 1, 2008; 21(1): 19 - 25.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
J. Frazao and M. Rodriguez
Secondary Hyperparathyroidism Disease Stabilization Following Calcimimetic Therapy
NDT Plus, January 1, 2008; 1(suppl_1): i12 - i17.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
A. L. M. de Francisco and F. Carrera
A New Paradigm for the Treatment of Secondary Hyperparathyroidism
NDT Plus, January 1, 2008; 1(suppl_1): i24 - i28.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
M. Chonchol and R. P. Wuthrich
Potential Future Uses of Calcimimetics in Patients with Chronic Kidney Disease
NDT Plus, January 1, 2008; 1(suppl_1): i36 - i41.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. Lomonte, M. Antonelli, N. Losurdo, G. Marchio, B. Giammaria, and C. Basile
Cinacalcet is effective in relapses of secondary hyperparathyroidism after parathyroidectomy
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2056 - 2062.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. Drueke, D. Martin, and M. Rodriguez
Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
G. Jean, C. Chazot, and B. Charra
Six cases of successful cinacalcet cessation in haemodialysis patients treated for secondary hyperparathyroidism
Nephrol. Dial. Transplant., July 1, 2007; 22(7): 2102 - 2103.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
K. J. Martin and E. A. Gonzalez
Metabolic Bone Disease in Chronic Kidney Disease
J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
O. Dorsch
Use of cinacalcet in a patient on long-term dialysis with end-stage renal failure and refractory secondary hyperparathyroidism
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 637 - 640.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J. Q Hudson
Secondary Hyperparathyroidism in Chronic Kidney Disease: Focus on Clinical Consequences and Vitamin D Therapies
Ann. Pharmacother., September 1, 2006; 40(9): 1584 - 1593.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.